Loomis Sayles & Co. L P Trims Position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Loomis Sayles & Co. L P cut its stake in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 3.2% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,467,027 shares of the specialty pharmaceutical company’s stock after selling 49,096 shares during the period. Loomis Sayles & Co. L P’s holdings in Supernus Pharmaceuticals were worth $53,048,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Barclays PLC increased its holdings in Supernus Pharmaceuticals by 88.3% during the 3rd quarter. Barclays PLC now owns 108,788 shares of the specialty pharmaceutical company’s stock worth $3,393,000 after acquiring an additional 51,005 shares during the period. Geode Capital Management LLC grew its position in shares of Supernus Pharmaceuticals by 5.3% during the 3rd quarter. Geode Capital Management LLC now owns 1,482,051 shares of the specialty pharmaceutical company’s stock valued at $46,218,000 after purchasing an additional 74,438 shares in the last quarter. Franklin Resources Inc. increased its holdings in shares of Supernus Pharmaceuticals by 7.6% in the third quarter. Franklin Resources Inc. now owns 29,981 shares of the specialty pharmaceutical company’s stock worth $987,000 after purchasing an additional 2,121 shares during the period. Empowered Funds LLC purchased a new stake in shares of Supernus Pharmaceuticals in the fourth quarter worth $1,498,000. Finally, Smartleaf Asset Management LLC boosted its stake in Supernus Pharmaceuticals by 219.1% during the fourth quarter. Smartleaf Asset Management LLC now owns 1,267 shares of the specialty pharmaceutical company’s stock valued at $47,000 after buying an additional 870 shares during the period.

Insider Transactions at Supernus Pharmaceuticals

In other news, VP Padmanabh P. Bhatt sold 9,477 shares of the business’s stock in a transaction that occurred on Tuesday, February 4th. The shares were sold at an average price of $39.70, for a total value of $376,236.90. Following the completion of the sale, the vice president now directly owns 10,149 shares in the company, valued at approximately $402,915.30. The trade was a 48.29 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, SVP Jonathan Rubin sold 927 shares of the company’s stock in a transaction on Friday, February 21st. The shares were sold at an average price of $39.15, for a total transaction of $36,292.05. Following the completion of the sale, the senior vice president now directly owns 7,853 shares of the company’s stock, valued at $307,444.95. This trade represents a 10.56 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 11,104 shares of company stock worth $440,263. 9.30% of the stock is currently owned by corporate insiders.

Supernus Pharmaceuticals Stock Performance

Shares of NASDAQ:SUPN opened at $32.42 on Friday. The firm has a market capitalization of $1.81 billion, a PE ratio of 30.30 and a beta of 0.83. Supernus Pharmaceuticals, Inc. has a 52-week low of $25.53 and a 52-week high of $40.28. The firm has a fifty day moving average of $35.26 and a 200 day moving average of $35.02.

Analyst Ratings Changes

A number of brokerages have weighed in on SUPN. Cantor Fitzgerald restated a “neutral” rating and issued a $36.00 target price on shares of Supernus Pharmaceuticals in a research note on Wednesday, February 26th. StockNews.com cut shares of Supernus Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Monday.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.